BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer

Breast Cancer Research

Table 2 BluePrint standard and dual subtypes in relation to pathological complete response and survival

		Pathological complete response		Overall survival		Breast cancer-specific survival
		aOR (95% CI)	p	aHR (95% CI)	p	aHR (95% CI)	p
Standard subtype	HER2-type	Ref		Ref		Ref
	Other	0.17 (0.09–0.32)	< 0.001	1.33 (0.58–3.03)	0.50	1.35 (0.54–3.39)	0.52
Dual subtype	HER2-single-type	Ref		Ref		Ref
	Other	0.15 (0.09–0.24)	< 0.001	2.04 (1.08–3.84)	0.028	2.38 (1.20–4.70)	0.014

aOR adjusted Odds Ratio, aHR adjusted Hazard Ratio, 95% CI 95% Confidence Interval, p p-value; Ref reference

ISSN: 1465-542X